Tag: global

Merck requests FDA authorization for COVID-19 antiviral pill

By Joseph Choi

Read the full article from The Hill, here.

Merck has said that its pill, which targets the enzyme that allows the COVID-19 virus to make copies of itself, is likely effective against COVID-19 variants, including the highly infectious delta variant.

The U.S. government already has a supply agreement with Merck to acquire about 1.7 million courses of molnupiravir if it receives emergency use authorization from the FDA.

Moderna, Racing for Profits, Keeps Covid Vaccine Out of Reach of Poor

By Rebecca Robbins

Read the full article from The New York Times, here.

Moderna, whose coronavirus vaccine appears to be the world’s best defense against Covid-19, has been supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and earning billions in profit.

After developing a breakthrough vaccine with the financial and scientific support of the U.S. government, Moderna has shipped a greater share of its doses to wealthy countries than any other vaccine manufacturer, according to Airfinity, a data firm that tracks vaccine shipments.

The Delta variant is detected in 99% of U.S. cases, according to C.D.C.

By Víctor Manuel Ramos

Read the full article from The New York Times, here.

The C.D.C.’s Covid Data Tracker, reporting results for the two-week period ending on Sept. 11, put the B.1.617.2 lineage of Delta at 99.4 percent among variants of concern, with two other Delta lineages tracked at 0.2 percent and 0.1 percent, the Mu variant — first detected in January in Colombia — at 0.1 percent and several other, unidentified variants at 0.2 percent. That data is based on thousands of sequences provided every week through the C.D.C.’s national genomic surveillance efforts, according to the agency’s website.

A new study found half of Covid patients had lingering symptoms one year later

By Pam Belluck

Read the full article from The New York Times, here.

One year after becoming ill with the coronavirus, nearly half of patients in a large new study were still experiencing at least one lingering health symptom, adding to evidence that recovery from Covid-19 can be arduous and that the multifaceted condition known as “long Covid” can last for months.

The study, published Thursday in the journal The Lancet, is believed to be the largest to date in which patients were evaluated one year after being hospitalized for Covid. It involved 1,276 patients admitted to Jin Yin-tan Hospital in Wuhan, China, who were discharged between Jan. 7 and May 29, 2020.

The prospect of booster shots is igniting a global health debate

By Daniel E. Slotnik and Noah Weiland

Read the full article from The New York Times, here.

As the Delta variant rages around the world, a heated debate has arisen over whether public health officials should recommend booster shots.

On one side are global health officials who contend that available vaccines would be better used to inoculate high-risk people in poor nations where few have gotten the shots.

On the other are leaders and health officials in wealthier countries, who are setting aside doses for more vulnerable people who may need additional doses to protect them from the virus.